Isolation, Culture and Identification of Undifferentiated Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSCs) Derived from the Human Umbilical Cord
[1]
Moustafa A. H. El-Nawasany, Histology & Cytology Department, College of Medicine, Al-Azhar University, Cairo, Egypt.
[2]
Elsayed G. E. Khedr, Histology & Cytology Department, College of Medicine, Al-Azhar University, Cairo, Egypt.
[3]
Moustafa E. E. Motawee, Histology & Cytology Department, College of Medicine, Al-Azhar University, Cairo, Egypt.
[4]
Zeinab A-B Ali, Histology & Cytology Department, College of Medicine, Suiz Canal University, Ismailia, Egypt.
[5]
Hosam E. H. Kamel, Obstetric & Gynecology Department, College of Medicine, Al-Azhar University, Cairo, Egypt.
[6]
Tamer M. M. Abu-Amara, Histology & Cytology Department, College of Medicine, Al-Azhar University, Cairo, Egypt.
Wharton’s Jelly-derived Mesenchymal stem cells (WJ-MSCs) have been found to be an alternative source of stem cells for the regenerative medicine. This is as WJ-MSCs have potential for differentiation, self-renewal and unique immunomodulatory properties. Aim of the work: This work was conducted to assess our lab and staff capabilities in our Tissue Culture and Medical Genetics Unit to isolate, culture, identify and characterize WJ-MSCs derived from the adult human umbilical cord to be used for clinical applications in the future. Material and Methods: WJ-MSCs were isolated from the human umbilical cord collected from late-gestation pregnancy after cesarean section. Isolated WJ-MSCs cultured as P0 and recultured as P1. After confluency, WJ-MSCs were collected and characterized for surface markers expression using flow cytometry technique. Results: WJ-MSCs isolated in this study were positive for CD44, CD90, CD105 and negative for CD34. These findings suggest that WJ-MSCs appeared to be readily obtainable and highly proliferative cell lines that come from noninvasive source. Conclusion: isolated WJ-MSCs may be a good noninvasive source for stem cell therapy and regenerative medicine in the future. However, further studies should be done to evaluate its use as an allogenic cell source and expression of other markers in relation to cell immunogenicity.
Stem Cells, Mesenchymal Cells, Wharton’s Jelly, Tissue Culture, Umbilical Cord, Flowcytometry
[1]
Cai J, Weiss ML, Rao MS,et al. (2004):In search of "stemness". ExpHematol; 32: 585-598.
[2]
Minguell JJ, Erices A, Conget P, et al. (2001): Mesenchymal stem cells. ExpBiol Med; 226:507-520.
[3]
Uchida N, Buck DW, He D, Reitsmma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL, et al. (2000):Direct isolation of human central nervous system stem cell. Proc Natl AcadSci; 97:14720-14725.
[4]
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH, et al. (2001):Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng; 7:211-228.
[5]
Lee SW, Wang X, Chowdhury NR, Roy-Chowdhury J, et al. (2004): Hepatocyte transplantation: state of the art and strategies for overcoming existing hurdles. Ann Hepatol; 3:48-53.
[6]
De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A, et al. (2007): Isolation of amniotic stem cell lines with potential for therapy. Nat Biotech; 25:100-106.
[7]
Fuchs JR, Hannouche D, Terada S, Zand S, Vacanti JP, Fauza DO,et al. (2005):Cartilage engineering from ovine umbilical cord blood mesenchymal progenitor cells. Stem Cells; 23:958-964.
[8]
Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, Troyer D,et al. (2003):Matrix cells from Wharton's jelly form neurons and glia. Stem Cells; 21:50-60.
[9]
Kobayashi K, Kubota T, Aso T, et al. (1998):Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alphasmooth muscle actin. Early Hum Dev; 51: 223-233.
[10]
Fu YS, Shih YT, Cheng YC, Min MY, et al. (2004):Transformation of human umbilical mesenchymal cells into neurons in vitro. J Biomed Sci; 11: 652-660.
[11]
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC, et al. (2004):Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells; 22:1330-1337.
[12]
Carlin R, Davis D, Weiss M, Schultz B, Troyer D, et al. (2006): Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. ReprodBiol Endocrinol; 4: 1-13.
[13]
Freshney MG, Alcorn MJ, Richmond LJ, Holyoake TL,et al. (1994):Efficient isolation of human CD34 positive hemopoieticprogenitor cells by immune panninga. Stem Cells; 12(1): 114-124.
[14]
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. (2006): Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy; 8(4): 315–7.
[15]
Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV, et al. (2013): Wharton's Jelly-Derived Mesenchymal Stem Cells: Phenotypic Characterization and Optimizing Their Therapeutic Potential for Clinical Applications. Int J MolSci; 14(6): 11692–712.
[16]
Zhu H, Mitsuhashi N, Klein A, Barsky LW, Weinberg K, Barr ML, et al. (2006): The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells; 24(4):928– 35.
[17]
Barker TH, Hagood JS. (2009): Getting a grip on Thy-1 signaling. Bba-Mol Cell Res; 1793(5): 921–3.
[18]
Duff SE, Li CG, Garland JM, Kumar S, et al. (2003): CD105 is important for angiogenesis: evidence and potential applications. Faseb J; 17(9): 984–92.
[19]
Deans RJ, Moseley AB. (2000): Mesenchymal stem cells: Biology and potential clinical uses. ExpHematol; 28(8): 875–84.
[20]
Semenov OV, Malek A, Bittermann AG, Voros J, et al. (2009): Engineered polyelectrolyte multilayer substrates for adhesion, proliferation, and differentiation of human mesenchymal stem cells. Tissue Eng Part A; 15: 2977-2990.
[21]
Schneider RK, Pu¨ llen A.(2010): Long-term survival and characterization of human umbilical cord-derived mesenchymal stem cells on dermal equivalents. Differentiation 79, 182–193.
[22]
Xu HH, Zhao L, Detamore MS, Takagi S, et al. (2010): Umbilical cord stem cell seeding on fast-resorbable calcium phosphate bone cement. Tissue Eng. Part A; 16: 2743-2753.
[23]
Anzalone R, Lo Iacono M, Corrao S, et al.(2010):New emerging potentials for human Wharton’s jelly mesenchymal stem cells: Immunological features and hepatocyte-like differentiate capacity. Stem Cells Dev; 19: 423-438.
[24]
Zhang HT, Fan J. (2010): Human Wharton’s jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells. Differentiation ; 79: 15-20.
[25]
Alaminos M, Pe´rez-Ko¨ hler B. (2010): Transdifferentiation potentialities of human Wharton’s jelly stem cells towards vascular endothelial cells. J. Cell. Physiol. 223: 640-647.
[26]
Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB, et al. (2010): Researching into the cellular shape, volume and elasticity of mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic force microscopy. J Cell Mol Med 12(2): 537-552.
[27]
Kadner A, Zund G, Maurus C, et al. (2004): Human umbilical cord cells for cardiovascular tissue engineering: A comparative study. Eur J CardiothoracSurg; 25: 635– 641.
[28]
Troyer DL, Weiss ML. (2008):Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells; 26: 591-599.
[29]
Zeddou M, Briquet A.(2010): The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. 363: 1439-1441.
[30]
Dominici M, Le Blanc K, Mueller I, et al. (2006): Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy; 8: 315-317.
[31]
Solanki A, Kim JD, Lee KB, et al. (2008): Nanotechnology for regenerative medicine: Nanomaterials for stem cell imaging. Nanomedicine (Lond); 3: 567-578.
[32]
Wang HS, Hung SC, Peng ST, Huang CC, et al. (2004): Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells, 22(7): 1330-1337.
[33]
Haasters F, Prall WC, Anz D, Bourquin C, et al. (2009): Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. Journal of anatomy; 214(5): 759-767.
[34]
Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, et al. (2003): Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci; 10: 228-241.
